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The stoichiometric complex formed between human leukocyte elastase and a synthetic MeO-Sue-Ala-Ala-Pro-Val 
chloromethyl ketone inhibitor was co-crystallized and its X-ray structure determined, using Patterson search methods. 
Its structure has been crystallographically refined to a final R value of 0.145 (8.0 and 2.3 A). The enzyme structure is 
very similar to that recently observed in a complex formed with the ovomucoid third domain from turkey [(1986) EMBO 
J. 5,2453-24581. The rms deviation of all a-carbon atoms is 0.32 A. The peptidic inhibitor is bound in a similar overall 
conformation as the ovomucoid binding segment. Covalent bonds are formed between Val-PI of the inhibitor and His-57 
NE2 and Ser-195 OG of the enzyme. The carbonyl carbon is tetrahedrally deformed to a hemiketal. The valine side chain 
is arranged in the Sl pocket in the g- conformation. 
Elastase; Polypeptide inhibitor; Crystal structure; Serine proteinase; (Human leukocyte) 
1. INTRODUCTION 
Human leukocyte elastase (EC 3.4.21.37) is a 
lysosomal proteinase capable of degrading many 
connective tissue proteins such as elastin and 
destroying invading bacteria. Excessive leakage of 
this enzyme and reduced levels of functional 
natural inhibitors result in severe tissue damage, as 
observed for example in pulmonary emphysema, 
cystic fibrosis and adult respiratory distress syn- 
drome [ 1,2]. Its importance as a pathogenic agent 
in various diseases has stimulated the search for 
protein inhibitors and synthetic inhibitors [3,4]. 
In order to understand the specificity of HLE 
and to rationalize the design of potent, selective in- 
Correspondence address: W. Bode, Max-Planck-Institute fur 
Biochemie, D 8033 Martinsried, FRG 
Abbreviations: HLE, human leukocyte elastase; 0MTKY3, 
ovomucoid third domain from turkey; MPCMK, methoxy 
succinyl-Ala-Ala-Pro-Val chloromethyl ketone; MPM, 
methoxy succinyl-Ala-Ala-Pro-Val methylene; HLE-MPM, 
covalent complex formed between MPCMK and HLE; MeO- 
Sue, methoxy succinyl; Vam, C-(methylene) valyl 
hibitors we have recently determined the X-ray 
crystal structure of HLE in its molecular complex 
with an ovomucoid inhibitor third domain from 
turkey (OMTKY3) [5]. Together with sequencing 
methods also the peptide sequence of HLE was 
established [5,6]. The HLE turned out to be a 
characteristic trypsin-like serine proteinase, with 
several surface segments possessing, however, a 
quite unique conformation. 
The subsite specificity of HLE has been explored 
using peptidyl substrates and inhibitors with vary- 
ing peptidic moieties [7-lo]. In agreement with 
modeling results derived from its spatial structure 
[5] HLE exhibits a clear preference for Pl residues 
with medium-sized alkyl side chains such as valine. 
Specificity effects on binding and reactivity have 
been demonstrated up to the P6 position [ 111. Ex- 
cellent correlation was observed between peptide 
nitroanilide hydrolysis, peptide bond cleavage and 
chloromethyl ketone inhibition [7]. The most ef- 
fective chloromethyl ketone inhibitor for HLE 
found thus far is MeO-Sue-Ala-Ala-Pro-Val 
chloromethyl ketone (MPCMK), which was shown 
to provide protection against induced emphysema 
in rat [l]. 
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Chloromethyl ketones with distinct peptidyl 
moieties are potent, specifically reacting inhibitors 
of serine proteinases forming stable covalent com- 
plexes which are well suited for crystallographic 
studies [ 1 l-141. We have co-crystallized the com- 
plex formed between MPCMK and HLE and 
determined its molecular structure. In the follow- 
ing we report its refined structure, with particular 
emphasis on the interactions of the MeO-Sue 
group and of the Pl-valyl residue with the enzyme. 
2. MATERIALS AND METHODS 
Human leukocyte elastase (EC 3.4.21.37) was kindly denated 
by Drs S. Neumann and H. Lang of Merck AG (Darmstadt, 
FRG). MeO-Sue-Ala-Ala-Pro-ValCHzCl (MPCMK) was kindly 
provided by Dr J. Powers of the Georgia Institute of 
Technology (Atlanta, USA). All chemicals were purchased 
from Merck (Darmstadt). 
HLE (9 mg/ml) was inhibited by a lo-fold molar excess of 
MPCMK at pH 6.5 for 30 min at 20°C. Unbound inhibitor was 
removed by dialysis. The stoichiometric complex was crystal- 
lized at 20°C in 1.2 M to 1.7 M ammonium sulphate, buffered 
with 0.1 M Tris-HCl to pH 9 and 8, respectively, using the 
hanging drop vapour diffusion technique. Short, almost 
isometric crystals of hexagonal shape, rounded edges and 
diameters up to 0.15 mm were obtained. According to Laue’s 
symmetry and systematic extinctions these crystals are of hex- 
agonal space group P63. The cell constants are a = b = 74.2 A, 
c = 70.6 A, cy = ,5 = 90°, y = 120”. These crystals contain one 
complex per asymmetric unit and show reflections to almost 
2.0 A resolution. 
X-ray intensity data were collected on rotation/precession 
cameras using graphite monochromatized CuK, radiation. 
From 3 native crystals soaked in 2.5 M ammonium sulphate at 
pH 8, 20 260 reflections to 2.3 A were evaluated, using the 
FILME program as modified by W.S. Bennett, jr. These data 
were merged and scaled by means of the PROTEIN program 
package [IS] yielding 7390 unique reflections which represent 
75% of all data expected at a 2.3 A resolution (with 35% com- 
pleteness in the most outer shell from 2.4 to 2.3 A). The final 
R merge (defined as CII - (I) I /ElII) is 0.081. 
The orientation of the HLE component in the crystals was 
determined by the rotation function in Patterson space using a 
model Patterson map (2400 highest peaks, 3-15 A shell) 
calculated with the HLE component of the final HLE- 
OMTKY3 complex (R value of 0.162 with 1.8 A data [16]) and 
the crystal Patterson map (calculated with intensity data from 
8 to 3.5 A). The positioning of the HLE molecule in the unit cell 
was achieved by a translation function search using programs 
written by E.E. Lattmann and intensity data from 8 to 3.5 A. 
A similar result was obtained with a correlation coefficient 
searching program of S.J. Remington. The rotational and 
translational parameters were further refined with the Fourier 
transform fitting program TRAREF [17]. The crystallographic 
R value (defined as c( I IF,1 - IF,1 l)/cl F,I) of the HLE 
model placed and oriented according to the resulting 
parameters was 0.39 for 8 to 3.5 A data. 
A 3 A 2F, -F, Fourier map calculated with Sim-weighted 
model phases displayed clear electron density for the MPM in- 
hibitor in addition to most of the HLE component. This in- 
hibitor was constructed by linking a MeO-Sue group (MSUl41) 
to an Ala-151-Ala-161-Pro-171-Val-181 peptide, whose valyl 
residue had been converted into a valyl methylene with 
tetrahedral geometry at the carbonyl carbon (Vam-181) [13,18]. 
This inhibitor structure was modeled into the electron density 
on a PS330 interactive display (Evans and Sutherland) using the 
PSFRODO version [19] of FRODO [20]. The enzyme-inhibitor 
model was refined within 7 macrocycles using the energy 
restraint crystallographic refinement EREF [21] and energy 
parameters mentioned recently [22]; all nonbonded restraint 
parameters for Ser-195 OG and for the Vam-181 methylene 
were set to zero to allow their unbiased approach to Vam-181 
carbonyl and His-57 NE2. Fourier and difference Fourier maps 
were repetitively inspected at the graphics display to correct 
gross model errors. 
The intensity data used were gradually extended to a resolu- 
tion of 2.3 A. Solvent molecules were inserted at 
stereochemically reasonable positions if the difference electron 
density exceeded 2~. Finally, also individual B values were 
refined and averaged for all main chain and side chain atoms 
of each residue separately. The final model parameters are 
given in table 1. The final R value for 7103 reflections of be- 
tween 8 and 2.3 A resolution is 0.145. 
Fig.1. Complete model of the complex (leaving out all solvent molecules) of HLE (thin connections) and the MPM inhibitor (thick 
connections). 
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3. RESULTS 
After extensive refinement he polypeptide chain 
of HLE can be traced from the amino-terminal 
residue Ile-16 to Arg-36, from Gly-39 to Gly-145 
Table 1 
Final model parameters of the HLE-MPM structure 
Number of active protein atoms 1686 
Number of active solvent atoms 162 
rms standard deviation from target values 
Bond lengths 0.022 A 
Bond angles 2.79” 
Total internal energy - 1186 kcal/mol 
Resolution range 8-2.3 A 
Number of unique reflections used for 
refinement 7104 
R value 0.145 
Mean B value 13 Aa 
B value limits 5.0-60.0 A2 
Estimated mean coordinate error from 
agreement between observed and 
calculated structure factor 
According to Luzzati [32] 0.20 A 
According to Cruickshank [33] 0.13 A 
and from Arg-148 to Gln-243. Because HLE is pre- 
sent as a single chain (as shown by SDS-PAGE), 
the missing intermediate residues, Gly-38 and seg- 
ment Arg-146-Asn-147 (which are defined in 
HLE-OMTKY3 [5]), are strongly disordered in the 
crystal structure. The last visible residue, Gln-243, 
is relatively poorly defined by electron density. Ac- 
cording to carboxy-terminal sequencing data for 
medullasin [23] there might be a consecutive 
arginine residue at the carboxy-terminus, which is 
completely disordered. Except for this Arg-244 
(see table 2) the electron density map is in agree- 
ment with the published amino acid sequence 
[631. 
Fig.1 shows the structure of the HLE-MPM 
complex in an orientation similar to that given for 
HLE-0MTKY3 [5]. The conformation of the HLE 
component is only very weakly affected by the dif- 
ferent bound inhibitors and by the quite different 
cell contacts; the rms deviation of all a-carbon 
atoms is 0.32 A, i.e. only slightly above the 
estimated coordinate errors (table 1). A few signifi- 
cant deviations are found at some exposed surface 
loops. A few sites, especially the side chains of 
Val-63A and Leu-223, and the loop 70-80 (com- 
prising the ‘Ca-loop’ in trypsin [24]) are better 
Table 2 
Sequence numbering of HLE due to topological similarity with chymotrypsinogen 
116 
A26 
R36 
I47 
H57* 
V64 
s74 
A84 
D95 
1105 
Nl15 
Al25 
4135 
Cl45 
4156 
L166 
VI85 
Cl93 
G207 
R217 
D226 
N236 
- 
VI7 Cl8 Cl9 
W27 P28 F29 
G38 G39 H40 
A48 P49 N50 
C58 v59 A60 
R65 V66 V67 
R75 R76 E77 
V85 486 R87 
P96 v97 N98 
L106 4107 L108 
All6 Nl17 VI18 
Q126 Cl27 RI28 
Cl36 L137 Al38 
RI46 N147 RI48 
El57 Ll58 Nl59+ 
Cl68 R177 RI78 
RI86 Gl86A Rl86B 
D194 s195 Cl96 
L208 1209 H210 
G218 G219 c220 
A227 F228 A229 
W237 I238 D239 
R20 
M30 
F41 
F51 
N61 
L68 
P78 
I88 
L99 
Nl09+ 
4119 
RI29 
Ml39 
Cl50 
VI60 
s179 
4187 
s197 
G211 
A220A 
P230 
S240 
R21 
v31 
C42 
V52 
V62 
G69 
T79 
F89 
LIOO 
Cl10 
VI20 
Ll30 
Cl40 
1151 
Tl61 
N180 
Al88 
PI98 
1212 
s221 
V213 
1241 
A22 
S32 
G43 
M53 
N63 
A70 
R80 
E90 
NlOl 
Sill 
Al21 
Cl31 
WI41 
Al52 
VI62 
VI81 
Cl89 
L199 
A213 
G222 
A232 
1242 
R23 
L33 
A44 
s54 
V63A 
H71 
481 
N92 
Dl02* 
All2 
Q122 
N132 
Cl42 
s153 
VI63 
Cl82 
VI90 
v200 
S214 
L223 
4233 
4243 
P24 
434 
T45 
A55 
R63B 
N72 
V82 
G93 
1103 
T113 
L123 
Cl33 
L143 
v154 
T164 
T183 
Cl91 
c201 
F215 
Y224 
F234 
H25 
L35 
L46 
A56 
A63C 
L73 
F83 
Y94 
VI04 
1114 
PI24 
VI34 
L144 
L155 
S165 
L184 
F192 
N202 
V216 
P225 
V235 
* active site residues; +, sugar attachment sites 
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Fig.2. Section of the Fourier map around the MPM inhibitor. The map was calculated with phases derived from a model from which 
the complete inhibitor, the side chains of Ser.195 and His-57 and solvent molecules 702, 1137, 1231 and 1233 were omitted. Contour 
surface (restricted to these groups) is at 0.8~. 
defined in this structure than in the HLE- 
OMTKY3 complex, presumably due to stabilizing 
crystal contacts. All solvent molecules buried 
within the HLE components have equivalent 
counterparts in both HLE complexes. 
Of the six related enzymes for which tertiary 
structures have been evaluated and deposited at the 
Brookhaven Protein Data Bank, HLE is 
topologically most equivalent [ 161 with porcine 
pancreatic elastase [25,26]. In table 2 HLE has 
been aligned relative to chymotrypsinogen on the 
basis of topological equivalences [16]. Similar to 
the HLE-OMTKY3 complex [5] and in agreement 
with findings upon peptide sequencing [6] two 
sugar chains (also shown in fig.1) are found, each 
N-asparagine-linked through N-acetyl-glucos- 
amines; the Asn-lOPlinked carbohydrate is only 
defined for this linking sugar and an a-1,6-bound 
L-fucopyranose, whereas in the second carbo- 
hydrate, at Asn-159, two additional sugar rings (a 
p-1 ,Clinked N-acetyl-glucosamine and a branch- 
ing mannose) are partially defined [ 161. 
As shown in fig.2, the electron density map 
clearly shows the juxtaposition of the MPM in- 
hibitor to the extended S4--+Sl binding site of 
HLE. The density around the Vam-181 carbonyl is 
tetrahedrally shaped. Between the methylene car- 
bon and the carbonyl carbon atoms of Pl residue 
Vam-181 and His-57 NE2 and Ser-195 OG of the 
enzyme, the densities defining inhibitor and en- 
zyme groups merge indicating covalent bond for- 
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mation and transition of the planar carbonyl group 
to a tetrahedral hemiketal (fig.3). 
In contrast to the four amino acid residues 
151-181, the MeO-Sue group is only poorly de- 
fined in the Fourier map. Experiments with alter- 
native phasing models indicate that the MeO-Sue 
location shown in the figures is the most occupied. 
In this conformation it has, however, un- 
favourable contacts with atoms of symmetry 
related molecules, especially with the side chain of 
another Phe-192. The next probable alternative 
position of MeO-Sue marked by disconnected elec- 
tron density lobes interpreted as solvent molecules 
702, 1137, 1231 and 1233 (fig.2) is along the 
Arg-217 side chain, which is in a slightly different 
conformation compared with HLE-OMTKY3 
(fig.4). 
The four amino acid residues of the inhibitor are 
in relatively similar positions (the rms deviation of 
all common atoms is 0.44 A) relative to the HLE 
binding site and in a similar conformation as the 
P4 to Pl residues of HLE-OMTKY3 (fig.4). 
Similar favourable intermolecular hydrogen bonds 
are formed between Ala-161 N and Val-216 0 
(2.8 A) and Val-216 N and Ala-161 0 (3.2 A). 
Ala-161 is, together with Ala-151, involved in 
several additional unspecific contacts with HLE 
residues Phe-215, Val-216 and Arg-217. Pro-171 
(P2), like Thr-171 of OMTKY3 (fig.4), is embed- 
ded in the very characteristic hydrophobic S2 
pocket of HLE, lined by the side chains of His-57 
Volume 234, number 2 FEBS LETTERS July 1988 
Fig.3. Section of the HLE-MPM structure around the bound inhibitor, with the inhibitor emphasized by thick lines. 
(facing it with its flat side), Leu-99, Phe-192 and 
Phe-215 (fig.3). 
The most significant deviations between both 
bound inhibitors are observed at their Pl residues, 
i.e. Leu-181 (OMTKY3) and Vam-181. Vam-181 is 
tilted leaving the CA position almost unchanged, 
but enabling the amido nitrogen to approach 
Ser-214 0 (to form an almost ideal hydrogen bond 
of 2.8 A length), and the bulky Vam side chain to 
avoid unfavourable contacts with the Sl pocket of 
HLE. Vam CB is displaced 1.0 A. The valyl side 
chain is arranged in the g- conformation (xl = 
- 57”). As a consequence of the shorter side chain 
of Vam-181, compared with Leu-181, the side 
chains of Val-190 and Val-216 (which are lining the 
pocket and are also g- rotamers) turn slightly into 
the Sl pocket (with displacements of 0.9 A at 216 
CGl and of 0.7 A at 190 CG2), and 191 0 moves 
towards Vam-181 CB, to shrink the incompletely 
refilled pocket. 
This tilting of Vam-181 furthermore allows its 
carbonyl carbon to move 1.2 A towards Ser-195 
OG, which in turn must only slightly rotate (0.6 A) 
to form a covalent bond under formation of a 
tetrahedral hemiketal group. That these displace- 
ments are not the result of the simultaneous forma- 
tion of the covalent bond 18Imethylene-57NE2 is 
demonstrated by the similar structures of enzyme- 
aldehyde complexes [27] which lack this latter 
bond. The carbonyl group of Vam-181 is oriented 
Fig.4. Section of the HLE-MPM structure around the MPM inhibitor (thick connections), overlayed with the identical or homologous 
residues of the HLE-OMTKY3 complex [5,16]. 
371 
Volume 234, number 2 FEBS LETTERS July 1988 
differently, with its oxygen, however, only slightly 
displaced 0.4 A out of the oxyanion hole. Ob- 
viously (fig.4) the HLE main chain around Gly-193 
follows this movement and still allows the forma- 
tion of a 2.7 A hydrogen bond from its amide 
nitrogen to Vam-181 0 (besides the other 3.3 A 
bond from Ser-195 N). 
4. DISCUSSION 
The rational design of potent synthetic peptidic 
inhibitors of HLE requires a detailed under- 
standing of the HLE binding site and of its interac- 
tion with the peptidyl moiety, as is currently only 
achieved by X-ray crystallography. To date we 
have been able to obtain, besides several HLE 
complexes with protein inhibitors like 0MTKY3 
[16], only crystals of free or PMSF substituted 
HLE of bad diffraction quality and thus un- 
suitable for soaking experiments with small syn- 
thetic inhibitors. This work represents the first 
example of the creation of HLE complex crystals 
by co-crystallization, to get a detailed picture of 
the interaction site. 
In general, the overall arrangement of the MPM 
inhibitor is similar to that one would expect from 
knowledge of the OMTKY3 binding segment, and 
the formation of two covalent bonds to enzyme 
reactive site groups are as observed in related 
enzyme-peptide inhibitor complexes [ 1 l- 141: the 
Pl residue of the inhibitor is pulled into the Sl 
pocket, with the strengthening of the hydrogen 
bond between its amido nitrogen and Ser-214 0, 
and with simultaneous pyramidalisation of its car- 
bony1 function and addition of Ser-195 OG. The 
structural state observed is similar to the presumed 
transition state of substrates during catalytic 
cleavage, and the movements and deformations 
mentioned are anticipated to be necessary to attain 
and to pass this transition state. 
Two sites of this inhibitor are of particular in- 
terest: 
(i) Binding to and modification of arginine 
residues [28] leads to inactivation of HLE, and 
Arg-217 localized closest to its reactive site residues 
and somewhat representing the S5 subsite [5] is 
most probably the cause of this inactivation. The 
MeO-Sue group (P5) could have been placed close 
to Arg-217, but seems to prefer another position. 
Nevertheless, a related P5 residue with an acidic 
372 
end group could prefer to interact with the 
guanidyl group of Arg-217, which in turn could be 
pulled out of the closed enzyme protein surface, 
thus giving rise to inactivating conformational 
changes at the reactive site (through Asp-226?). 
(ii) The comparison of the Pl residue Vam-181 
with Leu-181 in HEL-OMTKY3 demonstrates that 
the valine residue is (possibly also through covalent 
interactions with Ser-195 OG) slightly tilted at its 
main chain, thus avoiding unfavourable contacts 
of its bulky side chain which would occur if its CA- 
CB dihedral were identical to that in Leu-181. The 
slightly smaller space required by the valyl side 
chain is accommodated by the enzyme by small 
rotations of surrounding groups which lead to a 
slight reduction of the empty space available in the 
Sl pocket [ 161. Nevertheless, the pocket is not fully 
occupied; due to its hydrophobic nature [5], a sol- 
vent molecule is, however, not accepted. The side 
chain conformation of Vam-181 is g-, which 
makes it a less frequently observed but still 
favourable rotamer [29]. An isoleucine at Pl in an 
equivalent Kl conformation, with its CD atom in 
trans-position to CA (g--t rotamer), could fill the 
pocket better, thus explaining its slightly higher 
preference in substrates for HLE compared with 
valine [9]. 
Several potent protein inhibitors of HLE, 
especially those engineered to attain improved 
binding and stability properties, have a valine at 
Pl. In ovomucoid inhibitors, valine at Pl slightly 
reduces the binding properties compared with 
leucine [30], whereas semi-synthetically modified 
BPTI-based inhibitors gain in affinity by a 
Leu--+Val replacement [31]. This work giving the 
probable conformation of a bound Val-Pl residue 
provides an initial basis to model these structures. 
NOTE ADDED IN PROOF 
Unfortunately, we have overlooked two recent 
papers which report on the mechanism of HLE in- 
activation by this valine chloromethyl ketone [34] 
and on similar crystals of HLE complex with 
alanine chloromethyl ketone [35]. 
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